Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zoe Ciantra

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Nature Immunology|February 28, 2025
The rewired immune microenvironment in leukemiaZoe Ciantra, Varvara Paraskevopoulou, Iannis Aifantis
Cell|August 9, 2023
A membrane-associated MHC-I inhibitory axis for cancer immune evasionXufeng Chen, Qiao Lu, Hua Zhou, et al.
JAMA Oncology|August 28, 2020
Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical TrialJonathan D Schoenfeld, Glenn J Hanna, Vickie Y Jo, et al.
Blood Advances|March 19, 2026
Live-cell Pick-Seq (LiP-Seq): Interrogating ultra-rare mantle cell lymphoma persistent cells after CART19 therapyRan Xu, Gongwei Wu, Siobhan Rice, et al.
Blood Cancer Discovery|May 20, 2026
RAS pathway activation and microenvironmental adaptation as hallmarks of myeloid sarcomaBettina Nadorp, Audrey Lasry, Sanam Loghavi, et al.
Biorxiv : the Preprint Server for Biology|January 23, 2026
Multiomic characterization, early detection, and therapeutic targeting of myeloid sarcomaBettina Nadorp, Audrey Lasry, Sanam Loghavi, et al.
Nature Medicine|November 15, 2024
Author Correction: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trialSteven M Horwitz, Ajit J Nirmal, Jahan Rahman, et al.
Nature Medicine|June 17, 2024
Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trialSteven M Horwitz, Ajit J Nirmal, Jahan Rahman, et al.
Nature Medicine|January 22, 2021
Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanomaZhuting Hu, Donna E Leet, Rosa L Allesøe, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Nature Immunology|February 28, 2025
The rewired immune microenvironment in leukemiaZoe Ciantra, Varvara Paraskevopoulou, Iannis Aifantis
Cell|August 9, 2023
A membrane-associated MHC-I inhibitory axis for cancer immune evasionXufeng Chen, Qiao Lu, Hua Zhou, et al.
JAMA Oncology|August 28, 2020
Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical TrialJonathan D Schoenfeld, Glenn J Hanna, Vickie Y Jo, et al.
Blood Advances|March 19, 2026
Live-cell Pick-Seq (LiP-Seq): Interrogating ultra-rare mantle cell lymphoma persistent cells after CART19 therapyRan Xu, Gongwei Wu, Siobhan Rice, et al.
Blood Cancer Discovery|May 20, 2026
RAS pathway activation and microenvironmental adaptation as hallmarks of myeloid sarcomaBettina Nadorp, Audrey Lasry, Sanam Loghavi, et al.
Biorxiv : the Preprint Server for Biology|January 23, 2026
Multiomic characterization, early detection, and therapeutic targeting of myeloid sarcomaBettina Nadorp, Audrey Lasry, Sanam Loghavi, et al.
Nature Medicine|November 15, 2024
Author Correction: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trialSteven M Horwitz, Ajit J Nirmal, Jahan Rahman, et al.
Nature Medicine|June 17, 2024
Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trialSteven M Horwitz, Ajit J Nirmal, Jahan Rahman, et al.
Nature Medicine|January 22, 2021
Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanomaZhuting Hu, Donna E Leet, Rosa L Allesøe, et al.
Pageof 1